Pediatric diabetes: Potential for insulin degludec.
作者信息
Kalra Sanjay, Unnikrishnan Ambika Gopalakrishnan, Sahay Rakesh
机构信息
Department of Endocrinology, Bharti Hospital and B.R.I.D.E., Karnal, Haryana, India.
Chellaram Diabetes Institute, Pune, Maharashtra, India.
出版信息
Indian J Endocrinol Metab. 2014 Nov;18(Suppl 1):S6-8. doi: 10.4103/2230-8210.145036.
Abstract
摘要
相似文献
1
Pediatric diabetes: Potential for insulin degludec.儿童糖尿病：德谷胰岛素的潜力
Indian J Endocrinol Metab. 2014 Nov;18(Suppl 1):S6-8. doi: 10.4103/2230-8210.145036.
2
Treating to target in type 2 diabetes: the BEGIN trial programme.2型糖尿病的达标治疗：BEGIN试验项目
J Assoc Physicians India. 2014 Jan;62(1 Suppl):21-6.
3
Premix insulins in type 1 diabetes: the coming of degludec/aspart.预混胰岛素在 1 型糖尿病中的应用：地特胰岛素/门冬胰岛素的问世。
Expert Opin Drug Metab Toxicol. 2019 Apr;15(4):341-348. doi: 10.1080/17425255.2019.1585427. Epub 2019 Mar 18.
4
Insulin degludec, a long-acting once-daily basal analogue for type 1 and type 2 diabetes mellitus.德谷胰岛素，一种用于 1 型和 2 型糖尿病的长效每日一次基础胰岛素类似物。
Can J Diabetes. 2015 Feb;39(1):4-9. doi: 10.1016/j.jcjd.2014.02.019. Epub 2014 Jul 22.
5
A short-term cost-utility analysis of insulin degludec versus insulin glargine U100 in patients with type 1 or type 2 diabetes in Denmark.丹麦1型或2型糖尿病患者中德谷胰岛素与甘精胰岛素U100的短期成本-效用分析
J Med Econ. 2017 Mar;20(3):213-220. doi: 10.1080/13696998.2016.1245663. Epub 2016 Oct 24.
6
Switching to Degludec is Associated with Reduced Hypoglycaemia, Irrespective of Definition Used or Patient Characteristics: Secondary Analysis of the ReFLeCT Prospective, Observational Study.改用德谷胰岛素与低血糖发生率降低相关，无论采用何种定义或患者特征如何：ReFLeCT前瞻性观察性研究的二次分析
Diabetes Ther. 2020 Sep;11(9):2159-2167. doi: 10.1007/s13300-020-00875-1. Epub 2020 Jul 14.
7
Use of insulin degludec, a new basal insulin with an ultra-long duration of action, in basal-bolus therapy in type 1 and type 2 diabetes.使用胰岛素德谷胰岛素，一种具有超长作用时间的新型基础胰岛素，在 1 型和 2 型糖尿病的基础-餐时胰岛素治疗中。
Ann Endocrinol (Paris). 2013 Dec;74(5-6):487-90. doi: 10.1016/j.ando.2013.04.004. Epub 2013 Aug 23.
8
Insulin degludec. Uncertainty over cardiovascular harms.德谷胰岛素。心血管危害存在不确定性。
Prescrire Int. 2014 Jun;23(150):149.
9
The effect of insulin degludec on risk of symptomatic nocturnal hypoglycaemia in adults with type 1 diabetes and high risk of nocturnal severe hypoglycaemia (the HypoDeg trial): study rationale and design.德谷胰岛素对 1 型糖尿病成人患者夜间严重低血糖高风险及夜间症状性低血糖风险的影响（HypoDeg 试验）：研究原理和设计。
BMC Endocr Disord. 2019 Jul 23;19(1):78. doi: 10.1186/s12902-019-0408-x.
10
Evaluation of the cost-utility of insulin degludec vs insulin glargine in Sweden.评估在瑞典使用德谷胰岛素相对于甘精胰岛素的成本-效用。
J Med Econ. 2013 Dec;16(12):1442-52. doi: 10.3111/13696998.2013.852099. Epub 2013 Oct 25.
引用本文的文献
1
Recombinant Human Insulin in Global Diabetes Management - Focus on Clinical Efficacy.全球糖尿病管理中的重组人胰岛素——聚焦临床疗效
Eur Endocrinol. 2017 Apr;13(1):21-25. doi: 10.17925/EE.2017.13.01.21. Epub 2017 Apr 3.
2
Type 1 diabetes mellitus-common cases.1型糖尿病——常见病例。
Indian J Endocrinol Metab. 2015 Apr;19(Suppl 1):S76-7. doi: 10.4103/2230-8210.155409.
本文引用的文献
1
ISPAD Clinical Practice Consensus Guidelines 2014. Insulin treatment in children and adolescents with diabetes.《国际儿童青少年糖尿病研究学会2014年临床实践共识指南：糖尿病儿童和青少年的胰岛素治疗》
Pediatr Diabetes. 2014 Sep;15 Suppl 20:115-34. doi: 10.1111/pedi.12184.
2
Insulin Degludec Aspart: The First Co-formulation of Insulin Analogues.胰岛素德谷门冬双胰岛素：首个胰岛素类似物复方制剂
Diabetes Ther. 2014 Jun;5(1):65-72. doi: 10.1007/s13300-014-0067-x. Epub 2014 May 15.
3
Management of pediatric patients with type 1 diabetes.
Pediatr Ann. 2014 Mar;43(3):115-20. doi: 10.3928/00904481-20140221-11.
4
Insulin degludec's ultra-long pharmacokinetic properties observed in adults are retained in children and adolescents with type 1 diabetes.在成年 1 型糖尿病患者中观察到的德谷胰岛素的超长药代动力学特性在儿童和青少年中得以保留。
Pediatr Diabetes. 2014 Feb;15(1):27-33. doi: 10.1111/pedi.12116.
5
An update on the pharmacotherapy options for pediatric diabetes.儿童糖尿病药物治疗选择的最新进展。
Expert Opin Biol Ther. 2014 Mar;14(3):355-64. doi: 10.1517/14712598.2014.874413. Epub 2014 Jan 6.
6
Insulin degludec: a significant advancement in ultralong-acting Basal insulin.德谷胰岛素：超长效基础胰岛素的重大进展。
Diabetes Ther. 2013 Dec;4(2):167-73. doi: 10.1007/s13300-013-0047-6. Epub 2013 Nov 20.
7
Insulin degludec/insulin aspart administered once daily at any meal, with insulin aspart at other meals versus a standard basal-bolus regimen in patients with type 1 diabetes: a 26-week, phase 3, randomized, open-label, treat-to-target trial.每日一次在任意一餐中给予德谷胰岛素/门冬胰岛素，其他餐次给予门冬胰岛素，与 1 型糖尿病患者的标准基础-餐时胰岛素方案相比：一项 26 周、3 期、随机、开放标签、以目标为导向的试验。
Diabetes Care. 2012 Nov;35(11):2174-81. doi: 10.2337/dc11-2503. Epub 2012 Aug 28.
8
Insulin degludec in type 1 diabetes: a randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine.德谷胰岛素治疗 1 型糖尿病：新一代超长效胰岛素与甘精胰岛素的随机对照试验。
Diabetes Care. 2011 Mar;34(3):661-5. doi: 10.2337/dc10-1925. Epub 2011 Jan 26.
Zotero 插件